Kingenic Launches Qllerk Allergy Relief in India.

 17 November 2020

Kingenic Lifescience Pvt. Ltd. (India),is a research-led, integrated global pharmaceutical company, today announced that it has launched Qllerk-LM Allergy Relief (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film-coated tablets in Indian market, as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Combination aids relief from sneezing and runny nose due to allergic skin condition and reduces airway inflammation.

" India is one of the key markets for us and we are consistently looking to expand our product portfolio consistently. We believe that the launch of Qllerk-LM will help enhance and expand our presence in this segment." said, Manan Kinariwala, Founder & CEO - Kingenic Lifescience Pvt. Ltd. (India)



More Stories
Kingenic introduces QR packaging security

Counterfeiting products cause financial losses for legitimate brands, involve social costs and losses of unpaid tax for governments. Kingenic Lifescience has implemented quick response code system on our latest packaging material to enhance traceability.

Kingenic launches NSAID range in India

Kingenic announces the Indian launch of Kinamol, it is set to enter NSAID market.  NSAIDs represent a critically important class of medications, Kingenic is commited to launch several more product under this class.

Kingenic enters GI therapeutics market.

We identify gastrointestinal theapeutic as an important area of treatment. With our entry into GI segment, Kingenic is commited to make maximum impact in coming years.

Making medicine accessible by expanding our reach.

By expanding our core distribution capabilities, we help healthcare professionals to serve the patients who depend on them.